Atomwise
San Francisco, US · Founded 2015 · Delaware corporation · 10 known investors
Atomwise uses artificial intelligence and machine learning to discover novel small-molecule drugs, with a current focus on developing treatments for immune and inflammatory diseases.
Founders & leadership
RM
Robert MittendorffDirector
AS
Adam SeabrookDirector
LM
Linda MaxwellDirector
MV
Mike VarneyDirector
IW
Izhar WallachExecutive Officer, Director
YZ
Yan ZhaoExecutive Officer
SW
Stephen WorlandExecutive Officer, Director
GT
Gavin TeoDirector
MO
Matt OckoDirector
KS
Kiersten SteadDirector
AH
Abraham HeifetsExecutive Officer, Director, Promoter
Investors · 10
Aurum Venture PartnersPleasanton
Cerity Partners VenturesNew York
Creative Destruction Lab (CDL)Toronto · $50K – $250K
Draper AssociatesSan Mateo · $500K – $5M
Unruly CapitalLondon
B4 Capitalreported$10M – $50Mvia Raj Ganguly · board
DCVC (Data Collective)reportedPalo Alto · $5M – $25M
Dolby Family VenturesreportedSan Francisco
OS FundreportedPark Ridge · $1M – $2M
Vickers Venture PartnersreportedSingapore
Reported raises · per SEC filings
Form D private placements▶$19.8MraisedMar 2026 · 5 investors · BiotechnologyRule 506(b)
Officers, directors & promoters on the filing
- Stephen WorlandExecutive Officer, Director
- Adam SeabrookDirector
- Izhar WallachDirector
- Yan ZhaoExecutive Officer
- Mike VarneyDirector
- Robert MittendorffDirector
- Linda MaxwellDirector
- Offering amount
- $35M
- Amount sold
- $19.8M
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$44.3MraisedMar 2025 · 19 investors · BiotechnologyRule 506(b)
Officers, directors & promoters on the filing
- Robert MittendorffDirector
- Adam SeabrookDirector
- Linda MaxwellDirector
- Mike VarneyDirector
- Izhar WallachExecutive Officer, Director
- Yan ZhaoExecutive Officer
- Stephen WorlandExecutive Officer, Director
- Offering amount
- $50M
- Amount sold
- $44.3M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$123MraisedAug 2020 · 25 investors · BiotechnologyRule 506(b)
Officers, directors & promoters on the filing
- Izhar WallachExecutive Officer, Director
- Raj GangulyDirector
- Abraham HeifetsExecutive Officer, Director
- Matt OckoDirector
- Han LimExecutive Officer
- Offering amount
- $127M
- Amount sold
- $123M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$51.5MraisedJul 2018 · 31 investors · BiotechnologyRule 506(b)
Officers, directors & promoters on the filing
- Gavin TeoDirector
- Matt OckoDirector
- Kiersten SteadDirector
- Izhar WallachExecutive Officer, Director, Promoter
- Abraham HeifetsExecutive Officer, Director, Promoter
- Offering amount
- $51.5M
- Amount sold
- $51.5M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- San Francisco's Atomwise raises $44 million in Series C round for AI drug discovery - San Francisco Business Timesbizjournals.com · 2025
- Exclusive: AI biotech Atomwise hires new CEO, raises $45M Series Cendpoints.news · 2025
- Atomwise Raises $123 Million to Accelerate AI Drug Discovery | NVIDIA Technical Blogdeveloper.nvidia.com · 2020
- Atomwise secures $123 million in funding to help ‘drug the undruggable’ | AI Businessaibusiness.com · 2020
- Deep learning startup Atomwise raises $45Mtechcrunch.com · 2018